STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #751 by analyst upside · 2026-09-09
NGNE
Neurogene Inc.
Healthcare · Market Cap $763M · P/E 0x
ANALYST PRICE TARGET
+110.9%
implied upside to consensus target
Current Price $38.13
Consensus Target $80.43
Bull Target $166.0
Bear Target $46.0
Analysts Covering 7
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
7
Hold
0
Sell
0
52-Week Low $15.93
52-Week High $43.66
YTD Return +89.1%
FUNDAMENTALS
Market Cap $763M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-5.05
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $15.93
52-Week High $43.66
Current Price $38.13
Bear Target $46.0
Bull Target $166.0
● Now $38.13 ● Target $80.43
TRADING DATA
Avg Volume 238K
YTD Return +89.1%
Analyst Count 7
Consensus Buy
Upside to Target +110.9%
Last Updated 2026-09-09

ANALYST SUMMARY

Neurogene Inc. (NGNE) is currently trading at $38.13 with a Wall Street consensus price target of $80.43, implying potential upside of 110.9% over the next 12 months. 7 analysts currently cover NGNE, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $166.0, while the most cautious has a target of $46.0.

NGNE operates in the Healthcare sector with a market capitalisation of $763M. The stock is up 89.1% year-to-date and is currently trading near the upper end of its 52-week range of $15.93 – $43.66.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for NGNE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity - Reiterated
Buy → Buy 2026-08-12 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-08-12 62% win rate (8 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-08-12 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-06-09 31% win rate (48 calls)
Canaccord Genuity - Reiterated
Buy → Buy 2026-04-06 Building track record
Canaccord Genuity ● Initiated
Buy 2026-02-27 Building track record
LifeSci Capital ● Initiated
Outperform 2026-01-26 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-01-13 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
43
out of 100
Coverage depth
16/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →